Cortex's CEO to Speak at the Techvest Global Healthcare Conference in London on May 13, 2004.Business Editors/High-Tech Writers Techvest Global Healthcare Conference 2004 IRVINE, Calif.--(BUSINESS WIRE)--April 29, 2004 Cortex Pharmaceuticals, Inc., (AMEX AMEX See: American Stock Exchange : COR), announced that Roger G. Stoll, Ph.D., Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. has accepted an invitation to speak at the Rodman & Renshaw Techvest Global Healthcare Conference on Thursday, May 13th at 9:25 AM BST (convention) BST - British Summer Time. The name for daylight-saving time in the UK GMT time zone. . Cortex is one of 150 invited public and private companies to present at this conference to be held at the Claridge's Hotel in London on May 12-14, 2004. Dr. Stoll will provide an update on Cortex's AMPAKINE(R) drug development program, including the progress made on their Phase I compound, CX717. A review of the Company's current financial status and what their "Orphan Drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the " business strategy could potentially mean to shareholders over the next several years will also be discussed. A live audio webcast of the presentation can be accessed by logging into the website at http://www.wallstreetwebcasting.com/webcast/rrshq2/cor/. An audio replay of the presentation will also be available for 30 days after the conference. About Cortex Pharmaceuticals: Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , Alzheimer's disease and anxiety disorders. (http://www.cortexpharm.com/) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion